Bristol-Myers Squibb Company vs Johnson & Johnson — Stock Comparison
Bristol-Myers Squibb Company (BMY) and Johnson & Johnson (JNJ) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Bristol-Myers Squibb Company and Johnson & Johnson are evenly matched on Q·Score (7/10 each). Johnson & Johnson scores higher on Sentiment, reflecting stronger analyst and market sentiment. Analyst consensus targets imply greater upside for JNJ (+0.8%) than for BMY (-1.2%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 47% return on equity and 19% profit margins.
⚠ analyst sentiment is cautious.
High-quality business with 26% return on equity and 21% profit margins.
⚠ earnings contracting 1% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
BMY vs JNJ: which stock scores better overall?
Based on Q·Score, Bristol-Myers Squibb Company (BMY) scores 7/10 versus Johnson & Johnson (JNJ) at 7/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: BMY or JNJ?
Bristol-Myers Squibb Company (BMY) scores higher on Growth (8.1/10 vs 5/10). Bristol-Myers Squibb Company reports revenue growth (5.7% YoY) while Johnson & Johnson reports (6.6% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is BMY or JNJ more attractively valued?
Johnson & Johnson (JNJ) scores higher on Valuation (6.5/10 vs 5.9/10). BMY trades at 10.2× P/E versus JNJ at 22.0×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about BMY vs JNJ?
There are 24 analysts covering BMY with a consensus price target of $66.21, and 22 analysts covering JNJ with a consensus target of $272.50. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: BMY or JNJ?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 8.8/10). Net profit margin: BMY at 18.9%, JNJ at 21.5%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: BMY or JNJ?
Johnson & Johnson (JNJ) scores higher on Financial Health (6.5/10 vs 6.1/10). Market beta: BMY at 0.23, JNJ at 0.23. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of BMY and JNJ?
Bristol-Myers Squibb Company (BMY) has a market capitalisation of $136.9B, while Johnson & Johnson (JNJ) has a market cap of $651.3B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do BMY or JNJ pay dividends?
BMY pays a dividend yield of 3.76%, while JNJ pays a dividend yield of 1.98%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →